Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
FTH is expected to report earnings to fall 76.76% to -66 cents per share on November 13
Q3'26
Est.
$-0.66
Q2'26
Beat
by $1.32
The last earnings report on August 04 showed earnings per share of -283 cents, beating the estimate of -415 cents. With 76.66K shares outstanding, the current market capitalization sits at 537.22M.